日本多发性骨髓瘤患者皮下注射硼替佐米后的注射部位反应 - Suppr

Suppr

超能文献

Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

作者信息

Kamimura Tomohiko, Miyamoto Toshihiro, Takashima Shuichiro, Yokota Noriko, Chong Yong, Ito Yoshikiyo, Akashi Koichi

出版信息

Int J Hematol. 2012 Oct;96(4):525-7. doi: 10.1007/s12185-012-1167-x. Epub 2012 Sep 8.

DOI:10.1007/s12185-012-1167-x

PMID:22961216

Abstract

摘要

相似文献

Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

Int J Hematol. 2012 Oct;96(4):525-7. doi: 10.1007/s12185-012-1167-x. Epub 2012 Sep 8.

Subcutaneous bortezomib: a step towards optimised drug use.

Lancet Oncol. 2011 May;12(5):410-1. doi: 10.1016/S1470-2045(11)70098-5. Epub 2011 Apr 18.

An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.

Acta Haematol. 2015;133(1):29-30. doi: 10.1159/000362587. Epub 2014 Jul 1.

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.

Cutaneous lesion induced by a subcutaneous administration of bortezomib.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):284-6. doi: 10.1016/j.clml.2012.05.002. Epub 2012 May 24.

Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.

Cancer Chemother Pharmacol. 2014 Sep;74(3):653-7. doi: 10.1007/s00280-014-2555-0. Epub 2014 Aug 6.

Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.

J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1363-4. doi: 10.1111/j.1468-3083.2010.03643.x.

J Clin Oncol. 2012 Dec 20;30(36):e379-81. doi: 10.1200/JCO.2012.43.6519. Epub 2012 Nov 13.

[Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection].

Rinsho Ketsueki. 2014 May;55(5):570-2.

引用本文的文献

Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.

Patient Prefer Adherence. 2014 Jul 4;8:939-46. doi: 10.2147/PPA.S38142. eCollection 2014.

Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.

Int J Hematol. 2014 Aug;100(2):159-64. doi: 10.1007/s12185-014-1611-1. Epub 2014 Jun 14.

High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.

Int J Hematol. 2013 Dec;98(6):694-701. doi: 10.1007/s12185-013-1469-7. Epub 2013 Nov 19.

本文引用的文献

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.

Haematologica. 2012 Dec;97(12):1925-8. doi: 10.3324/haematol.2012.067793. Epub 2012 Jun 11.

Cutaneous lesion induced by a subcutaneous administration of bortezomib.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):284-6. doi: 10.1016/j.clml.2012.05.002. Epub 2012 May 24.

Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.

Anticancer Res. 2011 Jun;31(6):2297-302.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

Blood. 2010 Apr 22;115(16):3416-7. doi: 10.1182/blood-2010-02-271676.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

Haematologica. 2008 Dec;93(12):1908-11. doi: 10.3324/haematol.13285. Epub 2008 Sep 2.

Skin lesions induced by bortezomib.

Haematologica. 2005 Dec;90(12 Suppl):ECR44.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

作者信息

Kamimura Tomohiko, Miyamoto Toshihiro, Takashima Shuichiro, Yokota Noriko, Chong Yong, Ito Yoshikiyo, Akashi Koichi

出版信息

Int J Hematol. 2012 Oct;96(4):525-7. doi: 10.1007/s12185-012-1167-x. Epub 2012 Sep 8.

DOI:10.1007/s12185-012-1167-x

PMID:22961216

Abstract

摘要

相似文献

Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

Int J Hematol. 2012 Oct;96(4):525-7. doi: 10.1007/s12185-012-1167-x. Epub 2012 Sep 8.

Subcutaneous bortezomib: a step towards optimised drug use.

Lancet Oncol. 2011 May;12(5):410-1. doi: 10.1016/S1470-2045(11)70098-5. Epub 2011 Apr 18.

An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.

Acta Haematol. 2015;133(1):29-30. doi: 10.1159/000362587. Epub 2014 Jul 1.

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.

Cutaneous lesion induced by a subcutaneous administration of bortezomib.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):284-6. doi: 10.1016/j.clml.2012.05.002. Epub 2012 May 24.

Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.

Cancer Chemother Pharmacol. 2014 Sep;74(3):653-7. doi: 10.1007/s00280-014-2555-0. Epub 2014 Aug 6.

Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.

J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1363-4. doi: 10.1111/j.1468-3083.2010.03643.x.

J Clin Oncol. 2012 Dec 20;30(36):e379-81. doi: 10.1200/JCO.2012.43.6519. Epub 2012 Nov 13.

[Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection].

Rinsho Ketsueki. 2014 May;55(5):570-2.

引用本文的文献

Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.

Patient Prefer Adherence. 2014 Jul 4;8:939-46. doi: 10.2147/PPA.S38142. eCollection 2014.

Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.

Int J Hematol. 2014 Aug;100(2):159-64. doi: 10.1007/s12185-014-1611-1. Epub 2014 Jun 14.

High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.

Int J Hematol. 2013 Dec;98(6):694-701. doi: 10.1007/s12185-013-1469-7. Epub 2013 Nov 19.

本文引用的文献

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.

Haematologica. 2012 Dec;97(12):1925-8. doi: 10.3324/haematol.2012.067793. Epub 2012 Jun 11.

Cutaneous lesion induced by a subcutaneous administration of bortezomib.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):284-6. doi: 10.1016/j.clml.2012.05.002. Epub 2012 May 24.

Anticancer Res. 2011 Jun;31(6):2297-302.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

Blood. 2010 Apr 22;115(16):3416-7. doi: 10.1182/blood-2010-02-271676.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

Haematologica. 2008 Dec;93(12):1908-11. doi: 10.3324/haematol.13285. Epub 2008 Sep 2.

Skin lesions induced by bortezomib.

Haematologica. 2005 Dec;90(12 Suppl):ECR44.